enVVeno Medical (NASDAQ:NVNO – Get Rating) and Apyx Medical (NASDAQ:APYX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares enVVeno Medical and Apyx Medical's net margins, return on equity and return on assets.
Get
enVVeno Medical alerts:
| Net Margins | Return on Equity | Return on Assets |
| enVVeno Medical | N/A | -56.38% | -53.02% |
| Apyx Medical | -39.28% | -39.82% | -31.06% |
Insider and Institutional Ownership
23.1% of enVVeno Medical shares are owned by institutional investors. Comparatively, 65.6% of Apyx Medical shares are owned by institutional investors. 16.3% of enVVeno Medical shares are owned by insiders. Comparatively, 11.6% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares enVVeno Medical and Apyx Medical's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| enVVeno Medical | N/A | N/A | -$16.53 million | ($2.58) | -1.83 |
| Apyx Medical | $48.52 million | 1.85 | -$15.17 million | ($0.56) | -4.62 |
Apyx Medical has higher revenue and earnings than enVVeno Medical. Apyx Medical is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for enVVeno Medical and Apyx Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| enVVeno Medical | 0 | 0 | 0 | 0 | N/A |
| Apyx Medical | 0 | 1 | 3 | 0 | 2.75 |
Apyx Medical has a consensus price target of $6.00, suggesting a potential upside of 131.66%. Given Apyx Medical's higher probable upside, analysts plainly believe Apyx Medical is more favorable than enVVeno Medical.
Volatility and Risk
enVVeno Medical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Summary
Apyx Medical beats enVVeno Medical on 8 of the 12 factors compared between the two stocks.
About enVVeno Medical
(Get Rating)
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
About Apyx Medical
(Get Rating)
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
